Home > Insider Trading > Filing (0001209191-16-142355)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
873303	Sarepta Therapeutics Inc.	SRPT	Pharmaceutical Preparations (2834)	930797222

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1529297	T David Howton	215 First Street, Suite 415 Cambridge MA 02142	Svp, General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-09-19	8,000	$13.90	11,168	No	4	M	Direct
Common Stock	Disposition	2016-09-19	8,000	$50.00	3,168	No	4	S	Direct
Common Stock	Acquisiton	2016-09-19	464	$0.00	3,632	No	4	A	Direct
Common Stock	Acquisiton	2016-09-19	19,125	$0.00	22,757	No	4	A	Direct
Common Stock	Disposition	2016-09-19	1,304	$50.00	21,453	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Options (right to buy)	Disposition	2016-09-19	8,000	$13.90	8,000	$13.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
72,007	2016-02-27	2025-02-27	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
100% of the Restricted Stock Award ("RSA") granted on September 19, 2016 vests six months from the date of grant. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting.
15,300 RSAs vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, with an additional 3,825 RSAs vesting during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting.